Scott Alan Peslak, MD, PhD
he/him/his
Hematology
Accepting new patients
Sees patients age 18 and up
Penn Blood Disorders Center
Make an appointmentCall 215-615-6555
Penn Medicine Provider

About me

  • Gene Therapy Lead, Comprehensive Sickle Cell Program and Comprehensive Adult Thalassemia Program
  • Assistant Professor of Medicine (Hematology-Oncology)
  • Assistant Professor of Pediatrics (Hematology-Oncology)

I am a physician-scientist at the University of Pennsylvania and I care for patients in the Penn Medicine Comprehensive Sickle Cell Disease Program and Comprehensive Adult Thalassemia Program. In addition to my clinical focus on red cell disorders, I also run a laboratory studying novel regulators of fetal hemoglobin and new genetic and pharmacologic therapies for the treatment of sickle cell disease.

Education and training

  • Medical School: University of Rochester School of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

74 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

October 2025
dr scott peslak is conscience and aware that we left his office understanding everything we discussed, i appreciate when a physician takes time with his patients.
October 2025
i trust him with his knowledge, experience, experience, research and any treatment plan he recommends. he does not hesitate to collaborate with other area experts to reach the best care for his patients
September 2025
dr peslak has great bedside manners.
August 2025
excellent

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Peslak is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Cheng A.N., Peslak S.A., Sheth S., Sayani F., Lal A. High morbidity in adults with non-transfusion-dependent thalassemia referred to U.S. specialty centers , American Society of Hematology Annual Meeting, Orlando, FL: 2025

Castracani C.C., Bright M., Patel J., Peslak S.A., Cheng A., Breda L., Rivella S., Kwiatkowski J. Real-world comparative effects of curative and disease-modifying therapies on ineffective erythropoiesis in beta-thalassemia , American Society of Hematology Annual Meeting, Orlando, FL: 2025

Cheng A.N., Gimotty P., Margolis D., Peslak S.A., Al-Samkari H, Roe A.H., Kwiatkowski J.L. Development of a Prediction Model for Maternal Pregnancy Complications in Sickle Cell Disease , American Society of Hematology Annual Meeting, Orlando, FL: 2025

Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. Real-world safety profile of twice-daily deferiprone for iron overload in patients with thalassemia syndromes , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025

Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. Real-world safety profile of twice-daily deferiprone for iron overload in patients with sickle cell disease , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025

Cheng A.N, Peslak S.A., Sheth S., Sayani S., Lal A. High Morbidity in Adults with Non-Transfusion-Dependent Thalassemia Referred to U.S. Specialty Centers , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025

Al Ta’ani, O.; Mayrer, B.M.; Luche, N.M.; Siddique, S.M., Peslak, S.A.; Anderson, T.S.; Vajravelu, R.K. Impact of Diagnostic Serum Ferritin Thresholds on Prevalence of Iron Deficiency Anemia: A Cross-Sectional Analysis of U.S. Adults , JAMA Internal Medicine, Online Ahead of Print: 2025,e252311

Cheng A.N., Cohen J., Lundberg R.K., Sayani F.A., Chong E.A., Peslak S.A. Progressive Anaemia and Splenomegaly in an Adult with HbE/Beta Thalassaemia , 1st TIF Pan American Conference on Thalassaemia and Other Haemoglobin Disorders, Washington, DC.: 2025

Huang, P., Peslak, S.A., Shehu, V., Keller, C.A., Giardine, B., Shi, J., Hardison, R.C., Blobel, G.A., Khandros, E. Let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching , Blood, 143(19): 2024,1980-1991

Peslak S.A., Abbas T., Khandros E., Traxler E.A., Abdulmalik O., Giardine B.M., Keller C.A., Hardison R.C., Shi J., Blobel G.A. Protein Phosphatase 6 Complex: Novel Regulator of Fetal Hemoglobin and Potential Therapeutic Target in Sickle Cell Disease. , American Society of Hematology Annual Meeting, San Diego, CA: 2023

View all publications